New immunotherapy for CMV-positive glioblastoma
Part of Cancer clinical trials.
This trial tests a new immunotherapy that targets the CMV virus inside your glioblastoma tumor. It is for people who have already completed standard radiation and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a newly diagnosed glioblastoma and your tumor must be MGMT-unmethylated (a specific type).
- You must have tested positive for CMV (a common virus).
- You must have had surgery to remove the tumor (not just a biopsy).
- You must have completed standard radiation and temozolomide chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental 'vaccine' made from your own immune cells (dendritic cells). The vaccine is designed to train your immune system to attack the brain tumor. It is for people whose glioblastoma has returned or progressed after standard treatment.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial tests a personalized vaccine (made from your own cells) combined with a common chemotherapy drug, temozolomide, for people with newly diagnosed glioblastoma. The goal is to train your immune system to fight the tumor and hopefully slow its growth.
This trial tests a vaccine made from your own immune cells to fight glioblastoma, a type of brain cancer. It may help your body attack the cancer more effectively after standard treatments.
This trial is testing a new vaccine (Bvax) added to the usual chemotherapy and radiation for glioblastoma. It aims to train your immune system to fight the tumor and possibly improve outcomes.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.